RT Journal Article
SR Electronic
T1 Clinical evaluation of the Abbott Alinity SARS-CoV-2 spike-specific quantitative IgG and IgM assays in infected, recovered, and vaccinated groups
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.17.21251940
DO 10.1101/2021.02.17.21251940
A1 Narasimhan, Madhusudhanan
A1 Mahimainathan, Lenin
A1 Araj, Ellen
A1 Clark, Andrew E.
A1 Markantonis, John
A1 Green, Allen
A1 Xu, Jing
A1 SoRelle, Jeffrey A.
A1 Alexis, Charles
A1 Fankhauser, Kimberly
A1 Parikh, Hiren
A1 Wilkinson, Kathleen
A1 Reczek, Annika
A1 Kopplin, Noa
A1 Yekkaluri, Sruthi
A1 Balani, Jyoti
A1 Thomas, Abey
A1 Singal, Amit
A1 Sarode, Ravi
A1 Muthukumar, Alagarraju
YR 2021
UL http://medrxiv.org/content/early/2021/02/19/2021.02.17.21251940.abstract
AB The COVID-19 pandemic continues to impose a significant burden on global health infrastructure. While identification and containment of new cases remains important, laboratories must now pivot and consider assessment of SARS-CoV-2 immunity in the setting of the recent availability of multiple COVID-19 vaccines. Here we have utilized the latest Abbott Alinity semi-quantitative IgM and quantitative IgG spike protein (SP) serology assays (IgMSP and IgGSP) in combination with Abbott Alinity IgG nucleocapsid (NC) antibody test (IgGNC) to assess antibody responses in a cohort of 1236 unique participants comprised of naïve, SARS-CoV-2 infected, and vaccinated (including both naïve and recovered) individuals. The IgMSP and IgGSP assays were highly specific (100%) with no cross-reactivity to archived samples recovered prior to the emergence of SARS-CoV-2, including those from individuals with seasonal coronavirus infections. Clinical sensitivity was 96% after 15 days for both IgMSP and IgGSP assays individually. When considered together, the sensitivity was 100%. A combination of NC- and SP-specific serologic assays clearly differentiated naïve, SARS-CoV-2-infected, and vaccine-related immune responses. Vaccination resulted in a significant increase in IgGSP and IgMSP titers, with a major rise in IgGSP following the booster (second) dose in the naïve group. In contrast, SARS-CoV-2 recovered individuals had several fold higher IgGSP responses than naïve following the primary dose, with a comparatively dampened response following the booster. This work illustrates the strong clinical performance of these new serological assays and their utility in evaluating and distinguishing serological responses to infection and vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNot ApplicableAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UT Southwestern Medical Center IRB approved this study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesYes